Viridian Therapeutics Q2 EPS $(1.05) Misses $(1.02) Estimate, Sales $233.000K Beat $22.308K Estimate
Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(1.02) by 2.94 percent. This is a 5 percent decrease over losses of $(1.00) per share
Viridian lost more money per share than experts thought it would, and losses got bigger than last year. When a company loses more money than people expected, it tells us the business isn't moving as fast as hoped.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.